WaveMan
WaveMan · Company
ICU · Seastar Medical Holding Corp
> Search tickers & screens ⌘K
LIVE
← All companies

ICU SeaStar Medical (ICU) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001831868
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
12
13F, latest reported quarter

What the filings say about ICU

Insiders, 180 days
+$2.5K net bought
1 buyer

SeaStar Medical insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, SeaStar Medical Holding Corp insiders bought a net $2.5K of stock across 26 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Messinger Michael
Chief Financial Officer
BUY
2026-08-19 SECtraded 2026-08-18
750
$2.5K
-26.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 9, 2025.
  • The trade is 30.0% of the 2,500 shares held after it.
  • No other insider bought within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Messinger Michael bought about $2.5K of ICU on Aug 18, 2026; 12 funds added in the latest 13F quarter.
Baird Jennifer A
Director
BUY
2025-12-22 SECtraded 2025-12-19
4,200
$1.0K
+5.1%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jun 30, 2025.
  • +2.7% median (+2.7% mean) 90-day return after 2 previous buys.
  • The trade is 11.6% of the 36,200 shares held after it.
  • 1 other insider bought within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Baird Jennifer A bought about $1.0K of ICU on Dec 19, 2025; 1 other insider bought within 30 days and 12 funds added in the latest 13F quarter.
Messinger Michael
Chief Financial Officer
BUY
2025-12-11 SECtraded 2025-12-09
14,500
$5.1K
-23.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 82.9% of the 17,500 shares held after it.
  • 1 other insider bought within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Messinger Michael bought about $5.1K of ICU on Dec 9, 2025; 1 other insider bought within 30 days and 12 funds added in the latest 13F quarter.
Van Heel Kenneth
Director
BUY
2025-08-28 SECtraded 2025-08-27
10,000
$8.6K
-73.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Aug 26, 2025.
  • +99.0% median (+99.0% mean) 90-day return after 2 previous buys.
  • The trade is 20.2% of the 49,400 shares held after it.
  • 1 other insider bought within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Van Heel Kenneth bought about $8.6K of ICU on Aug 27, 2025; 1 other insider bought within 30 days and 12 funds added in the latest 13F quarter.
Van Heel Kenneth
Director
BUY
2025-08-28 SECtraded 2025-08-26
25,000
$22.2K
-73.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 22, 2023.
  • The trade is 63.5% of the 39,400 shares held after it.
  • 1 other insider bought within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Van Heel Kenneth bought about $22.2K of ICU on Aug 26, 2025, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 12 funds added in the latest 13F quarter.
26 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 21 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$2.5K over 180 days
+$2.5K over 90 days
more than 65% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
12 funds bought in last quarter
below 81% of Medical Devices
Revenue
+814.1% year over year
more than 99% of Medical Devices
Margin
-984.6% net margin
below 97% of Medical Devices
Buybacks
no share repurchases reported
Short interest
4.2% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
more than 59% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ICU

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-60.9%12M
-65%-43%-22%+0%2025-102025-122026-022026-042026-062026-082026-10 2025-12-09 · Messinger Michael bought $5.1K2026-08-18 · Messinger Michael bought $2.5K2025-12-19 · Baird Jennifer A bought $1.0K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ICU: institutional holders (13F)

13F holdings, latest reported quarter
BOOTHBAY FUND MANAGEMENT, LLC
245,200 sh
$899.9K
GEODE CAPITAL MANAGEMENT, LLC
49,593 sh
$182.0K
VANGUARD CAPITAL MANAGEMENT LLC
33,091 sh
$121.4K
UBS Group AG
32,199 sh
$115.2K
VANGUARD FIDUCIARY TRUST CO
13,692 sh
$50.2K

Congress trades in ICU

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ICU planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ICU mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$81.4K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$121.4K position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$32.1K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$21.6K position · as of 2026-05-31
0.0%
Dimensional U.S. Core Equity 2 ETF
$8.9K position · as of 2026-07-31
0.0%
Fidelity Nasdaq Composite Index Fund
$1.7K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $2.5K bought by insiders over 180 days, 12 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

ICU financials

Revenue growth
+814.1%
XBRL, annual
Net margin
-984.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.7M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-795.5%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.13x
long-term 2024-12-31 (18 months older than the period end) plus current 2024-12-31 (18 months older than the period end); equity 2026-06-30
Cash flow to debt
-23.86x
TTM operating cash flow over long-term 2024-12-31 (18 months older than the period end) plus current 2024-12-31 (18 months older than the period end)
Return on equity
-356.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-160.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-366.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$11.4M
market value at close 2026-10-26 on 2026-08-05 shares, plus long-term 2024-12-31 (18 months older than the period end) plus current 2024-12-31 (18 months older than the period end), minus cash 2021-12-31
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$1.2M$135.0K$0n/a
Gross profit$1.2M$135.0K$0n/a
Operating income-$12.2M-$17.8M-$14.2M-$11.6M
Net income-$12.2M-$24.8M-$26.2M-$12.2M
EPS (diluted)n/a-6.63-30.26-1.48
Operating cash flow-$13.6M-$16.0M-$10.3M-$7.8M
Long-term debtn/a$0$4.1M$7.7M
SEC XBRL, fiscal years, as known on 2026-10-28

ICU Stock Sonar score 6/7 axes

Find similar shapesCompare

ICU ranks highest on growth (99th percentile) and insider conviction (58th), and lowest on profitability (6th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
6
Inputs
  • Return on equity-356.9% · 8 pct, sector of 183
  • Return on assets-160.0% · 9 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-366.3% · 1 pct, sector of 188
Financial health
35
Inputs
  • Debt to equity0.13x · 64 pct, sector of 159
  • Cash flow to debt-23.86x · 6 pct, sector of 150
Growth
99
Inputs
  • Revenue growth, YoY+814.1% · 99 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
58
Inputs
  • Net Form 4 buying (codes P and S), 180d$2K · 63 pct, sector of 140
  • Insider buyers, 180d1 · 52 pct, sector of 142
Institutional and government
19
Inputs
  • Funds adding, latest quarter12 · 19 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
43
Inputs
  • Short interest, % of float+4.2% · 52 pct, sector of 241
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+13.7% · 35 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ICU filings, in plain words

Are SeaStar Medical insiders buying or selling ICU?

In the 180 days to 2026-10-28, SeaStar Medical insiders were net buyers, a net $2.5K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, SeaStar Medical insiders were net buyers of ICU, a net $2.5K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies